Correction

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (vol 20, pg 49, 2021)

LANCET NEUROLOGY (2021)

Volume 20, Issue 2, Pages E2-E2

DOI: 10.1016/S1474-4422(20)30368-9

Click your name to claim this paper and add it to your profile.